AMSTERDAM (dpa-AFX) - QIAGEN (QGEN) and Myriad Genetics (MYGN) have
collaborated to develop companion diagnostic tests in the field of cancer, the
companies said in a statement.

Myriad leverages its CLIA-certified, CAP-accredited lab platform, assay
development expertise and robust commercial infrastructure for clinical sample
testing.

QIAGEN will provide Sample to Insight solutions, including sample preparation,
its PCR, digital PCR (using the QIAcuity system), QIAseq next-generation
sequencing (NGS) technologies, instruments, as well as the QIAGEN Digital
Insights portfolio of bioinformatics.

Additionally, QIAGEN contributes GMP-certified product manufacturing
capabilities and globally established commercial channels.

The partnership also capitalizes on the combined FDA and worldwide regulatory
expertise of both companies, providing seamless compliance and integration in
clinical and companion diagnostic applications.

The companies noted that the initial project focus for the two companies will
involve collaborating with pharma partners to develop assays utilizing
next-generation sequencing workflows or QIAGEN's digital PCR platform, QIAcuity.



Copyright(c) 2023 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX